Losartan Potassium
Product Images NDC 67046-449

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 67046-449). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losart100.449

This is a description of a medication called Losartan Potassium. It is a tablet in the dosage of 100mg and comes in a bottle of 30 tablets. The medication is prescribed and its lot number is H160645 with the pill ID of E47. The GTIN is 0035704844930 and the S/N is 20125322 with an expiration date of 08/27/13. The medication is to be stored at a temperature between 20-25°C (68-7°F) with permitted excursions of 15-30°C (59-86°F). The medication is packaged by Contract Pharmacy Services-PA and each film-coated tablet contains Lo potassium USP 100mg. The usual adult dosage is not available, therefore one should check the package insert.*

FDA Label Image

Losart50.455

Losartan Potassium is a medication in the form of a film-coated tablet containing 50mg of Losartan potassium USP. It comes in a package of 30 tablets with an NDC number 67046-455-30. The lot number is H180845, and the pill ID is E46, with an expiration date of 06/27/19. The medication is manufactured by Aurobindo and has a store temperature of 20-25°C (68-77°F). The recommended dosage is provided in the package insert.*

FDA Label Image

Figure-1 (Losartan Fig1)

The text describes a study involving two medications, Atenolol and Losartan Potassium, and their effectiveness in reducing the primary endpoint. The study tracked patients over a period of 66 months and reported an adjusted risk reduction of 13%, with 9% of patients experiencing the primary endpoint.*

FDA Label Image

Figure-2 (Losartan Fig2)

This text provides information about a study comparing the effectiveness of Atenolol and Losartan Potassium on patients with fatal/non-fatal stroke. It indicates that the adjusted risk reduction was 25%, with a p-value of 0.001. The graph shows the study month timeline from 0 to 66 months.*

FDA Label Image

Figure 3 (Losartan Fig3)

This appears to be a table showing data for a medical study with various demographic subgroups. The primary endpoint events are being analyzed, and it seems that there are subgroups based on gender, race, age, previous history of venereal disease, and potassium levels. The table appears to show the number of events for each subgroup, but without the context of the study or further information, it is difficult to provide a more detailed description.*

FDA Label Image

Figure-4 (Losartan Fig4)

This appears to be a table showing the percentage of patients with and without an event, and a calculation of the risk reduction with Losttan Potassium compared to a placebo. The risk reduction is calculated to be 16.1% with a p-value of 0.022. However, it's not clear what the event being measured is, as there is no additional information in the text.*

FDA Label Image

Chemical Structure (Losartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.